肿瘤细胞治疗研究
ALL SOURCES
Engineering Interferon-γ-Enhanced Chimeric Antigen Receptor Macrophages via Lipid-Assisted Polymeric Nanoparticles for Cancer Immunotherapy.
目的 To develop an efficient strategy for in vivo engineering of M1-like CAR-Ms for cancer therapy. 方法 We designed a lentiviral vector encoding a CAR targeting BCMA and a cytokine cassette. Macrophages were transduced and
Vascular normalization by erianin unleashes CAR-T immunotherapy in glioblastoma.
异常肿瘤血管是限制免疫治疗（包括实体瘤中的CAR-T 细胞 疗法）疗效的主要屏障，它通过限制 T 细胞浸润并损害其功能活性发挥作用。
Engineered probiotics recruit CAR macrophages and establish immune memory to eradicate heterogeneous glioblastoma in mice.
在侵袭性原位GBM小鼠模型中，该策略在120天终点时实现了83%的生存率，相比单靶点对照组提高了5倍，并建立了有效对抗复发的持久免疫记忆。
Advances in CAR-T therapy for central nervous system tumors.
CAR-T 细胞疗法在中枢神经系统肿瘤中的应用已取得显著进展；
Acidity-targeting transition-aided universal chimeric antigen receptor T-cell (ATT-CAR-T) therapy for the treatment of solid tumors.
CAR-T 细胞用于治疗实体瘤时经常面临重大挑战，主要原因是肿瘤抗原的异质性。
Chimeric antigen receptor T cell therapy for glioblastoma: overcoming current barriers and strategies to enhance efficacy for therapeutic implications
胶质母细胞瘤（GBM）是一种高度恶性的原发性脑肿瘤，其特点是治疗选择有限且生存结局差。
CAR T cells: engineered immune cells to treat brain cancers and beyond.
恶性脑肿瘤属于治疗难度最大的恶性肿瘤类型。
A Review of Recent Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapy for Hepatocellular Carcinoma.
肝细胞癌（HCC）是最常见的原发性肝癌形式，构成重大全球健康负担。
Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma
这是一项早期 I 期注册临床试验，评估 CAR-T 细胞治疗胶质母细胞瘤的安全性、可行性及初步疗效。当前状态：尚未开始招募。计划入组 36 例。试验地点：中国 · 杭州（共 1 个中心，其中中国 1 个）。登记号：NCT07244666。
Enhanced anti-tumor efficacy of electroporation (EP)-mediated DNA vaccine boosted by allogeneic lymphocytes in pre-established tumor models.
我们的临床前研究结果表明，通过过继转移接种过疫苗的健康供体来源的同种异体淋巴细胞来增强EP介导的DNA疫苗接种，可提高抗肿瘤疗效。
MEMBER ACCOUNT
登录成功会直接打开下一页。
